Biotech

Medivation and Astellas Initiate Trial Evaluating Benefit of Continued Enzalutamide Treatment Beyond Disease Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

SAN FRANCISCO, CA and NORTHBROOK, IL: SAN FRANCISCO, CA and NORTHBROOK, IL -- (Marketwired) -- 11/12/13 -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (TOKYO: 4503), and Medivation, Inc. (NASDAQ: MDVN) ...

ProMetic's PBI-4050 Shown to Reduce Heart Fibrosis

LAVAL, QUEBEC: - PBI-4050 significantly reduces heart fibrosis in chronic kidney disease rat model - Significant reduction of fibrosis in the kidney and liver re-confirmed - Expands potential commercial opportunitie ...

Sarepta Therapeutics Announces FDA Considers NDA Filing for Eteplirsen Premature in Light of Recent Competitive Drug Failure and Recent DMD Natural History Data

CAMBRIDGE, MA: FDA Questions Dystrophin as a Biomarker Due to Failed Studies of Other Investigational Drugs for DMD; FDA Questions 6-Minute Walk Test Results for Eteplirsen, Suggesting Study Population Should Be Sta ...

Paladin Announces Extension of the Impavido(R) PDUFA Date by Three Months

MONTREAL, CANADA: MONTREAL, CANADA -- (Marketwired) -- 11/11/13 -- Paladin Labs Inc. ("Paladin") (TSX: PLB), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (F ...

Threshold Pharmaceuticals Announces New Data on the Combination of TH-302 and Avastin(R) (bevacizumab) in Recurrent Glioblastoma to Be Presented at WFNO/SNO

SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/11/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the comb ...

Atossa Genetics to Announce Third Quarter 2013 Results on Tuesday, November 12, 2013

SEATTLE, WA: SEATTLE, WA -- (Marketwired) -- 11/08/13 -- (NASDAQ: ATOS), The Breast Health Company™, today announced that it will issue financial results and corporate developments for the quarter ended Septemb ...

Horizon Pharma Announces Third Quarter 2013 Financial Results, Reports Net Revenue of $26.2 Million

DEERFIELD, IL: DUEXIS(R) Third Quarter Net Revenue of $23.5 Million, an Increase of 122% Versus Q2 2013; Conference Call and Webcast Today, November 8th at 8:00 a.m. ET ...

Notice of Paladin Labs' Third Quarter 2013 Results Conference Call

MONTREAL, CANADA: MONTREAL, CANADA -- (Marketwired) -- 11/07/13 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, will release its third quarter 2013 financial results on Thursday, ...

Advanced Proteome Therapeutics Corporation Advances Anti-Cancer Program

VANCOUVER, BRITISH COLUMBIA: VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 11/07/13 -- Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) is pleased to announce the achi ...

ProMetic Announces the Closing of its Common Share Offering

LAVAL, QUEBEC: LAVAL, QUEBEC -- (Marketwired) -- 11/07/13 -- ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") is pleased to announce that it has closed i ...